Education
About Us
Working with TipRanks
Follow Us
Britannia Life Sciences Inc (TSE:BLAB)
:BLAB
BLAB Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.14
Previous CloseN/A
Volume35.00K
Average Volume (3M)73.07K
Market Cap
C$16.23M
Enterprise ValueC$17.78M
Total Cash (Recent Filing)C$861.63K
Total Debt (Recent Filing)C$2.41M
Price to Earnings (P/E)―
Beta-1.52
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)1.93
Price to Sales (P/S)32.95
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained triple-digit TTM revenue growth indicates strong market demand and successful commercialization of products or partnerships. Over 2-6 months this supports scaling, higher sales leverage, and greater room to fund R&D and commercial expansion, improving long-term competitive position.
Free Cash Flow GenerationAn improving free cash flow profile and FCF-to-net-income >1 show the company can convert earnings into cash, reducing dependency on external financing. Durable FCF allows reinvestment in pipelines, supports partnerships, and cushions against revenue cyclicality over the medium term.
Improving Leverage ManagementTrend of improving debt-to-equity signals management focus on deleveraging and financial discipline. Lower leverage improves flexibility to fund R&D or M&A, reduces refinancing risk, and strengthens resilience to industry headwinds across the next several quarters.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow indicates the core business isn't generating sufficient cash from operations, forcing reliance on financing or non-recurring items. This structural cash shortfall can limit sustainable investment in pipelines and heighten liquidity risk over months.
Lack Of ProfitabilityChronic negative net margins and volatile operating profitability point to structural cost or commercialization inefficiencies. Without durable margin improvement, the company may struggle to translate revenue growth into sustainable earnings and shareholder returns over the medium term.
Low Equity Ratio / Financial InstabilityA low equity ratio and history of high leverage leave limited capital buffers against setbacks. This structural fragility increases vulnerability to funding shocks, constrains strategic options, and raises the risk that future growth could be impaired by financing constraints over coming quarters.
Britannia Life Sciences Inc News
BLAB FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
Britannia Life Sciences Inc lowest stock price was C$0.05 and its highest was C$0.14 in the past 12 months.
What is Britannia Life Sciences Inc’s market cap?
Britannia Life Sciences Inc’s market cap is C$16.23M.
When is Britannia Life Sciences Inc’s upcoming earnings report date?
Britannia Life Sciences Inc’s upcoming earnings report date is Mar 04, 2026 which is in 27 days.
How were Britannia Life Sciences Inc’s earnings last quarter?
Britannia Life Sciences Inc released its earnings results on Dec 01, 2025. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Britannia Life Sciences Inc overvalued?
According to Wall Street analysts Britannia Life Sciences Inc’s price is currently Overvalued.
Does Britannia Life Sciences Inc pay dividends?
Britannia Life Sciences Inc does not currently pay dividends.
What is Britannia Life Sciences Inc’s EPS estimate?
Britannia Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Britannia Life Sciences Inc have?
Britannia Life Sciences Inc has 162,254,330 shares outstanding.
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Britannia Life Sciences Inc reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
Currently, no hedge funds are holding shares in TSE:BLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.
Technical Analysis
Hemostemix
―
Innovotech
―
Sirona Biochem
―
Glow LifeTech
―
Telescope Innovations Corp
―